RankingsPricing
  1. US-listed companies
  2. ACADIA PHARMACEUTICALS INC
  3. Financials
  4. Research & development

ACADIA PHARMACEUTICALS INCACAD

Market cap
$3.9B
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 2024303-13.76%
Dec 31, 2023352-2.75%
Dec 31, 2022362+51.02%
Dec 31, 2021239-24.98%
Dec 31, 2020319+32.76%
Dec 31, 2019240+28.44%
Dec 31, 2018187+25.45%
Dec 31, 2017149+50.26%
Dec 31, 201699+34.41%
Dec 31, 201574+21.89%
Dec 31, 201461+126.79%
Dec 31, 201327+42.18%
Dec 31, 201219+8.58%
Dec 31, 201117

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)